Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
The herpes simplex virus (HSV) ICP34.5 null mutant 1716 replicates selectively in actively dividing cells and has been proposed as a potential treatment for cancer, particularly brain tumours. We present a clinical study to evaluate the safety of 1716 in patients with relapsed malignant glioma. Following intratumoural inoculation of doses up to 10(5) p.f.u., there was no induction of encephalitis, no adverse clinical symptoms, and no reactivation of latent HSV. Of nine patients treated, four are currently alive and well 14-24 months after 1716 administration. This study demonstrates the feasibility of using replication-competent HSV in human therapy.
Rampling
R
R
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Cruickshank
G
G
Papanastassiou
V
V
Nicoll
J
J
Hadley
D
D
Brennan
D
D
Petty
R
R
MacLean
A
A
Harland
J
J
McKie
E
E
Mabbs
R
R
Brown
M
M
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy* / Q000821:virology; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D015316:Genetic Therapy / Q000379:methods*; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000235:genetics / Q000254:growth & development / Q000472:pathogenicity*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy* / Q000821:virology; D016896:Treatment Outcome; D014774:Virulence; D014779:Virus Replication